Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:5
  • preuzimanja u poslednjih 30 dana:2

Sadržaj

članak: 4 od 210  
Back povratak na rezultate
2020, vol. 73, br. 3-4, str. 88-93
Poređenje serumskih nivoa interleukina-33 kod dece sa alergijskim bolestima respiratornog sistema
aUniverzitet u Novom Sadu, Medicinski fakultet + Univerzitet u Novom Sadu, Medicinski fakultet, Institut za zdravstvenu zaštitu dece i omladine
bUniverzitet u Novom Sadu, Medicinski fakultet
cUniverzitet u Novom Sadu, Medicinski fakultet + Klinički centar Vojvodine, Centar za laboratorijsku medicinu, Novi Sad

e-adresaborko.milanovic@mf.uns.ac.rs
Ključne reči: interleukin-33; oboljenja respiratornog sistema; interleukini; alergeni; respiratorna hiperosetljivost; dete; alergijski rinitis; astma; atopijska hiperosetljivost
Sažetak
Uvod. Dosadašnja ispitivanja ističu značaj interleukina-33 u patogenezi alergijskih bolesti disajnih puteva. Odnos interleukina-33 i pojedinih alergijskih bolesti disajnih puteva kao i njihovih karakteristika nije dovoljno preciziran. Osnovni cilj ovog istraživanja bio je odrediti vrednosti interleukina-33 u serumu kod dece sa alergijskom astmom i alergijskim rinitisom kao i ispitati odnos dobijenih vrednosti interleukina-33 sa pojedinim kliničkim karakteristikama ovih pacijenata. Materijal i metode. Izmerene su serumske vrednosti interleukina-33 kod ukupno 91 deteta. Ispitivanu grupu činilo je 39 dece sa alergijskom astmom i alergijskim rinitisom i 22 deteta koja su imala alergijsku astmu bez alergijskog rinitisa. Kontrolnu grupu činilo je 30 zdrave dece. Rezultati. Deca koja su imala alergijsku astmu udruženu sa alergijskim rinitisom, vrednosti interleukina-33 u serumu bile su signifikantno veće u odnosu na decu koja su imala alergijsku astmu bez alergijskog rinitisa (ch2 = 7,01; p = 0,008; p < 0,01). Obe grupe pacijenata su imale signifikantno veće vrednosti interleukina-33 u serumu u odnosu na zdravu decu (ch2 = 7,01; p = 0,008; p < 0,01). Korelacija između nivoa interleukina-33 u serumu i težine alergijske astme je statistički značajna (rs = 0,289; p = 0,024; p < 0,05). Zaključak. Serumske vrednosti interleukina-33 su značajno veće kod dece sa alergijskim bolestima disajnih puteva u odnosu na zdrave ispitanike. Značajno više vrednosti interleukina-33 u serumu imaju deca sa alergijskom astmom i alergijskim rinitisom u odnosu na decu sa alergijskom astmom bez alergijskog rinitisa. Pacijenti koji su imali više vrednosti interleukina-33 u serumu imali su i teži oblik alergijske astme.
Reference
Asaka, D., Yoshikawa, M., Nakayama, T., Yoshimura, T., Moriyama, H., Otori, N. (2012) Elevated levels of interleukin-33 in the nasal secretions of patients with allergic rhinitis. Int Arch Allergy Immunol, 158(Suppl 1):47-50
Augustine, J., Pavlou, S., Ali, I., Harkin, K.I., Ozaki, E., Campbell, M., Stitt, A.W., Xu, H., Chen, M. (2019) IL-33 deficiency causes persistent inflammation and severe neurodegeneration in retinal detachment. Journal of Neuroinflammation, 16(1): 251-251
Bahrami, M.S., Movahedi, M., Aryan, Z., Bahar, M.A., Rezaei, A., Sadr, M., et al. (2015) Serum IL-33 is elevated in children with asthma and is associated with disease severity. Int Arch Allergy Immunol, 168(3):193-6
Bonanno, A., Gangemi, S., Grutta, L.S., Malizia, V., Riccobono, L., Colombo, P., et al. (2014) 25-hydroxyvitamin D, IL-31, and IL-33 in children with allergic disease of the airways. Mediators Inflamm, 2014:520241
Brożek, J.L., Bousquet, J., Baena-Cagnani, C.E., Bonini, S., Canonica, G. W., Casale, T.B., van Wijk, R.G., Ohta, K., Zuberbier, T., Schünemann, H.J. (2010) Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision. Journal of Allergy and Clinical Immunology, 126(3): 466-476
Bush, A. (2019) Pathophysiological mechanisms of asthma. Frontiers in Pediatrics, 7: 68-68
Compalati, E., Ridolo, E., Passalacqua, G., Braido, F., Villa, E., Canonica, G.W. (2010) The link between allergic rhinitis and asthma: The united airways disease. Expert Review of Clinical Immunology, 6(3): 413-423
de Groot, E.P., Duiverman, E.J., Brand, P.L.P. (2010) Comorbidities of asthma during childhood: Possibly important, yet poorly studied. European Respiratory Journal, 36(3): 671-678
Ding, W., Zou, G.L., Zhang, W., Lai, X.N., Chen, H.W., Xiong, L.X. (2018) Interleukin-33: its emerging role in allergic diseases. Molecules, 23(7):1665
Fahy, J.V. (2015) Type 2 inflammation in asthma: Present in most, absent in many. Nature Reviews Immunology, 15(1): 57-65
GBD 2015 Chronic Respiratory Disease Collaborators (2017) Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma: 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med, 5(9):691-706, published correction appears in Lancet Respir Med. 2017; 5(10): e30
Global Initiative for Asthma (GINA) (2018) 2018 GINA report: Global strategy for asthma management and prevention. https://ginasthma.org/wp-content/uploads/2019/01/2018-GINA.pdf [updated 2018; cited 2020 Mar 15]
Guo, Z., Wu, J., Zhao, J., Liu, F., Chen, Y., Bi, L., Liu, S., Dong, L. (2014) IL-33 promotes airway remodeling and is a marker of asthma disease severity. Journal of Asthma, 51(8): 863-869
Haenuki, Y., Matsushita, K., Futatsugi-Yumikura, S., Ishii, K.J., Kawagoe, T., Imoto, Y., et al. (2012) A critical role of IL-33 in experimental allergic rhinitis. J Allergy Clin Immunol, 130(1):184-94
Hasan, A., Kochumon, S., Al-Ozairi, E., Tuomilehto, J., Ahmad, R. (2019) Association between adipose tissue interleukin-33 and immunometabolic markers in individuals with varying degrees of glycemia. Disease Markers, 2019: 1-16, 7901062
Imai, Y., Yasuda, K., Nagai, M., Kusakabe, M., Kubo, M., Nakanishi, K., Yamanishi, K. (2019) IL-33-induced atopic dermatitis-like inflammation in mice is mediated by group 2 innate lymphoid cells in concert with basophils. Journal of Investigative Dermatology, 139(10): 2185-2194.e3
Kapsali, T., Horowitz, E., Diemer, F., Togias, A. (1997) Rhinitis is ubiquitous in allergic asthmatics. J Allergy Clin Immunol, 99(1 Part 2): 138-138
Kostić, G., Ilić, N., Petrović, M., Marković, S., Vuletić, B., Igrutinović, Z. (2010) Indeks telesne mase dece sa astmom pre i posle jednogodišnje primene inhalatornih glikokortikosteroida. Medicinski pregled, vol. 63, br. 5-6, str. 409-413
Makrinioti, H., Toussaint, M., Jackson, D.J., Walton, R.P., Johnston, S.L. (2014) Role of interleukin 33 in respiratory allergy and asthma. Lancet Respiratory Medicine, 2(3): 226-237
Miller, A.M., Asquith, D.L., Hueber, A.J., Anderson, L.A., Holmes, W.M., Mckenzie, A.N., et al. (2010) Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res, 107(5):650-8
Momen, T., Ahanchian, H., Reisi, M., Shamsdin, S.A., Shahsanai, A., Keivanfar, M. (2017) Comparison of interleukin-33 serum levels in asthmatic patients with a control group and relation with the severity of the disease. Int J Prev Med, 8: 65-65
Murdaca, G., Greco, M., Tonacci, A., Negrini, S., Borro, M., Puppo, F., Gangemi, S. (2018) IL-33/IL-31 axis in immune-mediated and allergic diseases. International Journal of Molecular Sciences, 20(23): 5856-5856, 31766607
Raeiszadeh, J.S., Mahesh, P.A., Jayaraj, B.S., Madhunapantula, S.R., Holla, A.D., Vishweswaraiah, S., et al. (2014) Serum levels of IL-10, IL-17f and IL-33 in patients with asthma: A case-control study. J Asthma, 51(10):1004-13
Tahaghoghi-Hajghorbani, S., Ajami, A., Ghorbanalipoor, S., Hosseini-Khah, Z., Taghiloo, S., Khaje-Enayati, P., Hosseini, V. (2019) Protective effect of TSLP and IL-33 cytokines in ulcerative colitis. Autoimmunity Highlights, 10(1): 1-1
Wang, Y., Wang, L., Hua, S. (2017) Interleukin-33 in children with asthma: A systematic review and meta-analysis. Allergologia et Immunopathologia, 45(4): 387-392
Yang, Z., Liang, Y., Xi, W., Li, C., Zhong, R. (2011) Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population. Clinical and Experimental Medicine, 11(2): 75-80
 

O članku

jezik rada: engleski
vrsta rada: izvorni naučni članak
DOI: 10.2298/MPNS2004088M
primljen: 08.04.2020.
revidiran: 27.04.2020.
prihvaćen: 20.05.2020.
objavljen u SCIndeksu: 25.11.2020.